Taiwan Advance Bio-Pharmaceutical, Inc. Statistics
Taiwan Advance Bio-Pharmaceutical, Inc. (4186) Stock Statistics & Valuation Metrics
Total Valuation
Taiwan Advance Bio-Pharmaceutical, Inc. has a market cap or net worth of TWD 604.80M. The enterprise value is ―.
- Market Cap
- TWD 604.80M
- Enterprise Value
- ―
Share Statistics
Taiwan Advance Bio-Pharmaceutical, Inc. has 90,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 90,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Taiwan Advance Bio-Pharmaceutical, Inc.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 4.26%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 4.26%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 2.28M
- Profits Per Employee
- 175.29K
- Employee Count
- 160
- Asset Turnover
- 0.49
- Inventory Turnover
- 6.46
Valuation Ratios
The current PE Ratio of Taiwan Advance Bio-Pharmaceutical, Inc. is 40.59. Taiwan Advance Bio-Pharmaceutical, Inc.’s PEG ratio is -1.17.
- PE Ratio
- 40.59
- PS Ratio
- 1.78
- PB Ratio
- 2.31
- Price to FCF
- 29.59
- Price to Operating Cash Flow
- 11.18
- PEG Ratio
- -1.17
Income Statement
In the last 12 months, Taiwan Advance Bio-Pharmaceutical, Inc. had revenue of 364.79M and earned 28.05M in profits. Earnings per share was 0.31.
- Revenue
- 364.79M
- Gross Profit
- 227.30M
- Operating Income
- 29.00M
- Pretax Income
- 27.16M
- Net Income
- 28.05M
- EBITDA
- 48.67M
- Earnings Per Share (EPS)
- 0.31
Cash Flow
In the last 12 months, operating cash flow was 55.53M and capital expenditures -34.54M, giving a free cash flow of 20.99M billion.
- Operating Cash Flow
- 55.53M
- Free Cash Flow
- 20.99M
- Free Cash Flow per Share
- 0.23
Dividends & Yields
Taiwan Advance Bio-Pharmaceutical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.38%
- Earnings Yield
- 2.54%
Stock Price Statistics
- Beta
- 0.38
- 52-Week Price Change
- -48.90%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 39.96
- Average Volume (3m)
- 103.81K
Financial Position
Taiwan Advance Bio-Pharmaceutical, Inc. as a current ratio of 0.98, with Debt / Equity ratio of 95.65%
- Current Ratio
- 0.98
- Quick Ratio
- 0.90
- Debt to Market Cap
- 0.27
- Net Debt to EBITDA
- 2.71
- Interest Coverage Ratio
- 4.45
Taxes
In the past 12 months, Taiwan Advance Bio-Pharmaceutical, Inc. has paid -891.00K in taxes.
- Income Tax
- -891.00K
- Effective Tax Rate
- -0.03
Enterprise Valuation
Taiwan Advance Bio-Pharmaceutical, Inc. EV to EBITDA ratio is 20.19, with an EV/FCF ratio of 36.33.
- EV to Sales
- 2.19
- EV to EBITDA
- 20.19
- EV to Free Cash Flow
- 36.33
- EV to Operating Cash Flow
- 13.73
Balance Sheet
Taiwan Advance Bio-Pharmaceutical, Inc. has TWD 157.98M in cash and marketable securities with TWD 299.63M in debt, giving a net cash position of -TWD 141.65M billion.
- Cash & Marketable Securities
- TWD 157.98M
- Total Debt
- TWD 299.63M
- Net Cash
- -TWD 141.65M
- Net Cash Per Share
- -TWD 1.57
- Tangible Book Value Per Share
- TWD 2.98
Margins
Gross margin is 59.38%, with operating margin of 5.28%, and net profit margin of 4.52%.
- Gross Margin
- 59.38%
- Operating Margin
- 5.28%
- Pretax Margin
- 4.27%
- Net Profit Margin
- 4.52%
- EBITDA Margin
- 10.84%
- EBIT Margin
- 5.28%
Analyst Forecast
The average price target for Taiwan Advance Bio-Pharmaceutical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -6.27%
- EPS Growth Forecast
- -32.65%
